PDR Drug Update - September 2018

PDR MEMBER LOGIN:

Not a Member? Register Now

Email or Username

Password

Remember me

Forgot your password?

PDR Search

type drug name here... Required field
Home /

PDR Drug Update /

September 2018 /

Labeling Updates

email share print Close window

Email this page

Send the page "" to a friend, relative, colleague or yourself.

Your Name

Recipient's Email
Separate multiple email address with a comma

Message

We do not record any personal information entered above.

Thank you. Your email has been sent.

Share this page

Facebook Twitter Linkedin
Advertisement
eDrug Update - September 2018

Recent FDA Approvals

Orilissa (elagolix), AbbVie Inc.

Labeling Updates

K e y
Boxed Warning
Other Warnings^*

*Warnings and Precautions; Adverse Reactions; Drug Interactions; and Contraindications
Updates to Indications/Dosage
Other Updates^{^†}

^†Other labeling changes; added to PDR database

				Humira (adalimumab)
				Mavyret (glecaprevir/pibrentasvir)

Orilissa (elagolix) - RECENT FDA APPROVAL